共 234 条
[1]
Byrd JC(2013)Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 32-42
[2]
Furman RR(2013)Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 369 507-516
[3]
Coutre SE(2013)Cancer statistics, 2013 CA Cancer J Clin 63 11-30
[4]
Flinn IW(2006)Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma Br J Haematol 132 303-316
[5]
Burger JA(2011)Update on therapy of chronic lymphocytic leukemia J Clin Oncol 29 544-550
[6]
Blum KA(2014)Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia N Engl J Med 371 213-223
[7]
Grant B(2005)Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 4070-4078
[8]
Sharman JP(2005)Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 Blood 105 49-53
[9]
Coleman M(2012)Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia Blood 120 4684-4691
[10]
Wierda WG(2013)Targeting B-Cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies J Clin Oncol 31 128-130